Polymorphisms in DNA repair genes modulate survival in cisplatin/gemcitabine-treated non-small-cell lung cancer patients

Background: Impaired DNA repair capacity may favorably affect survival in cisplatin/gemcitabine-treated non-small-cell lung cancer (NSCLC) patients. We investigated the association of survival with genetic polymorphisms in X-ray repair cross-complementing group 1 and group 3 (XRCC3), xeroderma pigme...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Annals of oncology 2006-04, Vol.17 (4), p.668-675
Hauptverfasser:	de las Peñas, R., Sanchez-Ronco, M., Alberola, V., Taron, M., Camps, C., Garcia-Carbonero, R., Massuti, B., Queralt, C., Botia, M., Garcia-Gomez, R., Isla, D., Cobo, M., Santarpia, M., Cecere, F., Mendez, P., Sanchez, J.J., Rosell, R.
Format:	Artikel
Sprache:	eng
Schlagworte:	Antineoplastic agents Antineoplastic Combined Chemotherapy Protocols - adverse effects Antineoplastic Combined Chemotherapy Protocols - therapeutic use Biological and medical sciences Carcinoma, Non-Small-Cell Lung - drug therapy cisplatin Cisplatin - administration & dosage Deoxycytidine - administration & dosage Deoxycytidine - analogs & derivatives DNA Repair - genetics DNA repair genes gemcitabine Genotype Humans Lung cancer Lung Neoplasms - drug therapy Medical sciences non-small-cell lung cancer Pharmacology. Drug treatments Pneumology Polymorphism, Genetic polymorphisms Survival Analysis Tumors of the respiratory system and mediastinum XRCC3
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!